Biotech Values

[winchem21]

DYAX product looks like complement not competitor to Lomucin or the 2nd generation product GENR is developing for CF. GENR's products for CF are mucoregulators, while DYAX's product appears to be an anti-inflammatory....

Potential for orphan status for lomucin??? Perhaps this is incentive for continued talks with CF Foundation. One possible use of new funding is for phase II testing of Lomucin to gain this status....

Looking for another patent issued early 2004 to GENR for mucoregulating target based on Levit's WSJ November interview. GENR taking steps to protect IP in this area and intends to license this target to big pharma....

wc21